Paul Richardson | EBMT 2019 | Treatment options for transplant ineligible patients with NDMM

Paul Richardson | EBMT 2019 | Treatment of relapsed/refractory multiple myelomaПодробнее

What are new treatment options for newly-diagnosed multiple myeloma patients? Dr. Paul G. RichardsonПодробнее

Changing treatment approaches for transplant-ineligible myeloma: DRd, BiTEs and CAR-TПодробнее

Treatment options for transplant-ineligble myeloma patients: the promise of combination therapiesПодробнее

Treating Transplant Ineligible MyelomaПодробнее

Treatment Options For Frail Patients at Early Relapse | Paul Richardson, MD | IMS 2023Подробнее

Best Treatment Options for Transplant Ineligible Myeloma Patients: Doublets-Triplets?Подробнее

New Options To Treat Newly Dx, Relapsed Myeloma — Dr. Paul Richardson | MCRT Webcast July 11Подробнее

Dr. Paul Richardson on novel approaches for treating multiple myeloma | Dana-Farber Cancer InstituteПодробнее

Treatment for Transplant Eligible Myeloma Patients: Doublets-Triplets?Подробнее

Treatment approaches for transplant-eligible and transplant-ineligbile myeloma patientsПодробнее

Treatment Strategies for Transplant Ineligible Patients with Multiple MyelomaПодробнее

ASH Impact Series: Paul Richardson, MD - Examining the New FDA Approved Myeloma Drug ProductsПодробнее

Integrated Myeloma Management for Transplant-Eligible PatientsПодробнее

Treatment options for transplant-ineligible patients with multiple myelomaПодробнее

Treating Transplant-Ineligible Multiple MyelomaПодробнее

Therapy Options for Transplant-ineligible Multiple MyelomaПодробнее

Treating Transplant-Ineligible Multiple MyelomaПодробнее

CELMoDs® Mezigdomide | Paul Richardson, MD | IMS 2022Подробнее